Navigation Links
Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
Date:8/8/2012

BASKING RIDGE, N.J., Aug. 8, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA at 4:30 p.m. ET on August 14, 2012 at the InterContinental Boston Hotel. 

The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the groundbreaking results of the REG1 phase 2b trial (RADAR).  Additionally, a summary of the positive results of the FDA end-of-phase 2 meeting and a description of the resulting phase 3 development program and timeline, minimized for cost and maximized for probability of success, will be provided.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely and concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, provide a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3 
Regado's lead program, the anticoagulant system REG1, consists of two agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin) with the second being its complementary active control agent (anivamersen).  Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin.  REG1, recently completing phase 2b (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 has completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing shortly and will be indicated for antiplatelet therapy such as in treating diabetic vasculopathies.

ABOUT APTAMERS
Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the complementary specific active control agent of pegnivacogin. 

More information can be found at www.regadobio.com.

Contact:  Ellen McDonald, Chief Business Officer, Regado Biosciences, 1-908-580-2113, emcdonald@regadobio.com

Media Contact:
Tiberend Strategic Advisors, Inc.
1-212-827-0020
Andrew Mielach, amielach@tiberend.com


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
4. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
5. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
6. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
9. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , February 27, 2017 Now ... the pharmaceutical companies that are most successful at developing and ... ... you gave the same molecule to two different companies in ... Based on systematic, objective analysis of each company,s performance ...
(Date:2/27/2017)... -- Period October – December 2016 Revenues ... SEK -16.4 (-6.4) million Result after tax amounted to SEK ... dilution Cash flow from operating activities amounted to SEK -8.3 ... Period full year ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... Ind. , Feb. 24, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the Cowen ... at the Boston Marriott Copley Place on Tuesday, March ... A live webcast of the presentation can be ... archived for replay following the conference via Zimmer Biomet,s ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media ... system brings songs, movies, TV shows and much more apps for user exploration. Its ... An immersive view of 1280 x 720 provides crisp images with remarkable clarity and ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... March 2014. The company had 800 customers and 2,250 RCEs at the time ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... hair transplantation therapy, is proud to announce a new informational post on robotic ... procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can ...
(Date:2/27/2017)... ... 27, 2017 , ... New Jersey ranks among the top five states in ... the need for advanced services is growing. , Project WE vs C is ... collaboration with their non-profit partners in their fight against cancer and in support of ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design ... Edition of International Social Design Awards. , The 7th A' Social Design ... Governments and Institutions worldwide with realized projects and conceptual works. , The first ...
Breaking Medicine News(10 mins):